Fresenius Medical Care wins the 2007 Capital IR Award for the best Investor Relations in the Dax
June 21, 2007Fresenius Medical Care has been recognized by the German business magazine “Capital” and the German Association for Financial Analysis and Asset Management (Deutsche Vereinigung für Finanzanalyse und Asset Management or DVFA) as having the best Investor Relations among the companies on the Dax index. Chief Executive Officer and Chairman of the Management Board Dr. Ben Lipps and the head of Investor Relations, Oliver Maier, received the award during a gala event June 20 at the Städel art museum in Frankfurt.
This is the eleventh time “Capital” and the DVFA have ranked the Investor Relations activities of key German and European companies on the EuroStoxx 50, Dax, M-Dax, Tec-Dax and S-Dax indexes. More than 400 analysts from 250 European banks, funds and companies were surveyed for the contest. They rated the quality of the Investor Relations departments in respect of dedication to their target audience, transparency, track record and additional financial reporting. Fresenius Medical Care received 417 of a possible 500 points. By awarding more than 400 points, the jury rated the Investor Relations efforts as very good.
“We are very pleased about this exceptional award and thank our shareholders and analysts for their trust,“ said Oliver Maier. “For us, the prize is both confirmation and motivation. We are especially pleased about the timing as last year we successfully integrated the Renal Care Group, changed our legal form and converted the preference shares into ordinary shares. It wasn’t just the biggest acquisition in the history of our company that placed exceptional demands on our IR activities in the previous quarters.”
In the past year alone, the employees of Fresenius Medical Care’s Investor Relations department held more than 700 meetings with analysts and investors. In addition, they presented the world’s leading dialysis company at 25 road shows and 13 investor conferences in Europe, North America and Asia as well as at numerous events and to private investor associations. Fresenius Medical Care’s financial communications also include detailed quarterly and annual reports with comprehensive segment information, regular analyst and telephone conferences as well as providing a broad spectrum of information on the internet.
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
top